Want to join the conversation?
$ABBV received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for its chronic hepatitis C virus (HCV) regimen. Now in Phase 3 clinical trials, glecaprevir/pibrentasvir (G/P) is an investigational, pan-genotypic regimen being evaluated for the treatment of HCV genotypes 1-6.
$AAL is giving pay hikes to its employees but investors are sulking.
$APC stock tumbled more than 5.6% after last week's fatal home explosion in Firestone, Colorado prompted the company to close more than 3,000 wells for weeks.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.